Showing 7441-7450 of 9550 results for "".
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plast
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- LovelySkin.com Awarded Patent for Skin Care Product Designed to Heal While Moisturizing Dry Lips and Skinhttps://practicaldermatology.com/news/20140423-lovelyskincom_awarded_patent_for_skin_care_product_designed_to_heal_while_moisturizing_dry_lips_and_skin/2459259/Joel Schlessinger, MD (owner of LovelySkin.com) and his son, Daniel, were just awarded the patent for FixMySkin 1% hydrocortisone balm—a suite of products specifically designed to heal, not ju
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 stu
- Foamix Gains Five Additional US Patentshttps://practicaldermatology.com/news/20140421-foamix_gains_five_additional_us_patents/2459263/The United States Patent and Trademark Office (USPTO) issued Foamix five new patents covering its technologies. Foamix, a specialty pharmaceutical company, focuses on developing and commercializing proprietary topical foams. The additional five patents raises Foamix's number to 25 United
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorpo
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents.
- Cosmetic Treatments Jump 25 Percent in 2013: ASDS Surveyhttps://practicaldermatology.com/news/20140401-cosmetic_treatments_jump_25_percent_in_2013_asds_survey/2459283/The number of cosmetic procedures performed by members of the American Society for Dermatologic Surgery jumped to nearly 6.5 million in 2013 – an increase of 25 percent over the previous year, the ASDS Survey on Dermatologic Procedures shows.
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.